ProMIS Neurosciences, Inc.
$11.45
▼
-3.77%
2026-04-21 08:53:01
www.promisneurosciences.com
NCM: PMN
Explore ProMIS Neurosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$24.63 M
Current Price
$11.45
52W High / Low
$39.75 / $6.27
Stock P/E
—
Book Value
$-0.58
Dividend Yield
—
ROCE
3267.2%
ROE
-5.22%
Face Value
—
EPS
$-22.61
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
10
Beta
-0.15
Debt / Equity
—
Current Ratio
0.88
Quick Ratio
0.88
Forward P/E
-20.66
Price / Sales
—
Enterprise Value
$106.84 M
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$34.22
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Corcept Therapeutics Incorporated | $46.34 | 49.18 | $4.9 B | — | 6.68% | 15.02% | $91 / $28.66 | $6.11 |
| 2. | TScan Therapeutics, Inc. | $1.43 | — | $67.71 M | — | -64.64% | -71.28% | $2.57 / $0.88 | $2.16 |
| 3. | C4 Therapeutics, Inc. | $2.99 | — | $284.93 M | — | -32.05% | -44.44% | $3.82 / $1.09 | $2.65 |
| 4. | Monte Rosa Therapeutics, Inc. | $19.81 | — | $1.58 B | — | -14.1% | -16.94% | $25.77 / $3.51 | $3.56 |
| 5. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
| 6. | Lyell Immunopharma, Inc. | $24.89 | — | $559.6 M | — | -69.37% | -86.98% | $45 / $7.65 | $11.68 |
| 7. | Royalty Pharma plc | $49.52 | 27.78 | $28.52 B | 1.91% | 8.21% | 13.2% | $50.08 / $31.58 | $15.11 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -10.77 M | -11.75 M | -10.18 M | -7.46 M | -6 M | — |
| Net Profit | -10.67 M | -11.58 M | -10.12 M | -7.35 M | -0.24 M | — |
| EPS in Rs | -1.19 | -1.29 | -1.13 | -0.82 | -0.03 | 7.75 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -40.17 M | -16.83 M | -14.26 M | -23.38 M |
| Net Profit | -39.72 M | 2.78 M | -13.21 M | -18.06 M |
| EPS in Rs | -4.43 | 0.31 | -1.47 | -2.01 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 9.18 M | 18.91 M | 13.62 M | 6.92 M |
| Total Liabilities | 10.44 M | 2.42 M | 9.87 M | 8.27 M |
| Equity | -1.26 M | 16.49 M | 3.75 M | -1.35 M |
| Current Assets | 9.18 M | 18.91 M | 13.62 M | 6.9 M |
| Current Liabilities | 10.41 M | 2.22 M | 9.35 M | 6.41 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -28.12 M | -27.18 M | -10.84 M | -17.03 M |
| Investing CF | -0 M | -0 M | -0 M | -0 M |
| Financing CF | 20.94 M | 27.88 M | 17.75 M | 6.49 M |
| Free CF | -28.12 M | -27.18 M | -10.84 M | -17.04 M |
| Capex | — | — | — | -0 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 121.03% | 26.85% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-11-28 | 1:0.04 |
| 2022-06-28 | 1:0.0166667 |